An interventional study of Dietary intervention using cookies containing milk or egg low dose. and Dietary intervention with cow's milk or egg baked cookies high dose in Cow Milk Protein Allergy and Hen Egg Allergy, sponsored by Fundació Sant Joan de Déu. Completed at 1 site in Spain. Open to participants aged 12 Months to 6 Years. Per ClinicalTrials.gov, last updated 2025-06-03.
Sponsored by Fundació Sant Joan de Déu · Not applicable, Interventional, and Treatment
Food allergies are more common in children, especially in Western countries. Around 5 to 8% of children have at least one food allergy, compared to only 1-2% of adults. These allergies can really affect child's quality of life and create stress for the whole family. The most common foods that cause allergic reactions are cow's milk, egg, nuts, fish, and shellfish.
Until now, the usual way to manage a food allergy has been to completely avoid the food. But this can be hard, limiting kids diets and puts them at risk of accidental exposure, and may even cause nutritional problems.
Oral immunotherapy (OIT) has become and alternative treatment. It consists in giving very small amounts of the food allergen regularly to help the body get used to it. Some studies show this helps children build tolerance faster than just avoiding the food. But OIT also comes with risks, including allergic reactions during the treatment, some of which can be serious.
Some research is focusing on a gentler and safer option: giving children baked milk or baked egg. When milk or egg is baked (for example, in muffins or cookies), the high heat changes the proteins, making them less likely to cause allergic reactions. The heat breaks the parts of the protein that the immune system usually reacts to, and mixing them with wheat flour makes them even less reactive.
Interestingly, this doesn't work for every food, peanuts, for example, can actually become more allergenic when heated. But in the case of milk and egg, baking seems to be very helpful.
Giving baked milk or egg to allergic children has shown some immune system changes similar to OIT, but in a safer and more natural way. This can make life a lot easier, not just for the kids, but also for their families since it broadens their diet, improves their nutrition, and reduces stress in social situations.
Studies suggest that introducing baked milk and egg early on could also help kids become fully tolerant sooner.
At Sant Joan de Déu Hospital in Barcelona, doctors have been using OIT for milk and egg allergies since 2006 in children over 5 years old. While the treatment has helped many, not all children become fully desensitized, and some still react to milk or egg occasionally. The success rate is around 70%, and it's often less effective in children with severe allergies, like those who have had anaphylaxis.
This is a 12-month, prospective, randomized interventional study designed to evaluate immunological tolerance development in young children with confirmed cow's milk or egg allergy. The primary endpoint is the acquisition of clinical tolerance to raw or minimally processed forms of the allergen after structured dietary exposure to baked forms. The study integrates immunologic, clinical, and laboratory evaluations to assess the therapeutic potential and immunomodulatory effects of gradual allergen introduction.
Study Population Inclusion Criteria Age: 12 to 72 months (1 to 6 years). Milk Allergy Subgroup: Confirmed diagnosis based on at least one of the following: suggestive clinical history, positive skin prick test (SPT) ≥3 mm over negative control and/or specific IgE ≥0.35 kU/L to cow's milk or casein.
Egg Allergy Subgroup: Either: suggestive clinical history and sensitization (SPT or sIgE ≥0.35 kU/L to egg white or ovomucoid).
Exclusion Criteria Inability to obtain written informed consent. Any contraindication to epinephrine use (e.g., uncorrected congenital heart disease).
Ongoing consumption of baked milk or egg ≥3 times/week within the last 3 months.
Baseline Procedures and Immune Profiling (T0)
All participants will undergo:
Supervised Oral Food Challenge (OFC) with a standardized baked milk or egg product (e.g., muffin containing measured protein quantity), carried out under hospital supervision with immediate access to emergency care.
Blood Sampling for:
Quantitative allergen-specific IgE, IgG4, IgA to milk/egg and their major components (e.g., casein, ovomucoid).
Flow cytometry for T-cell phenotyping (CD4⁺CD25⁺FoxP3⁺ regulatory T cells). Cytokine profiling via ELISA or multiplex immunoassay: IL-4, IL-5, IL-10, IL-13, TGF-β.
Basophil Activation Test (BAT) using CD63/CD203c expression upon allergen stimulation.
Skin Prick Testing with commercial milk/egg extracts and baked food extracts, if available.
Randomization and Treatment Arms
Participants are stratified based on baked food OFC outcome:
A. OFC-Positive to Baked Product
Randomized 1:1 to:
Baked Group 1 (Low-dose exposure): Daily ingestion of baked product containing fixed dose (e.g., 0.0375 g milk protein or 0.11 g egg protein).
Control Group 1 (Strict avoidance): Elimination of all milk/egg and derivatives.
Non-tolerant to minimum baked dose: Excluded from active intervention; followed as observational cohort with repeated testing at 12 months.
B. OFC-Negative to Baked Product Progress to OFC with pasteurized milk or cooked egg. If tolerant → study exit.
If reactive, randomization into:
Baked Group 2 (High-dose exposure): Daily ingestion of baked food containing higher protein load (e.g., 0.55 g milk protein or 1.1 g egg protein).
Control Group 2 (Strict avoidance).
All OFCs use a standardized 6-step titration protocol with cumulative dosing and observation for ≥2 hours post-ingestion.
Dose Escalation and Monitoring After 6 months: Hospital-based supervised dose escalation (doubling daily intake) for Baked Groups 1 and 2.
Final Assessment (T1 - 12 months) Repeat OFC with unheated (raw) milk or cooked/raw egg. Repeat blood testing, SPT, and BAT.
Comparative analysis between baseline and T1 to determine:
Acquisition of tolerance (negative OFC). Immune modulation (e.g., shifts in IgE/IgG4 ratios, Treg expansion, cytokine profile normalization).
Predictive value of baseline biomarkers for outcome stratification.
This detailed protocol structure enables reproducibility, comparability, and the possibility of identifying immunological biomarkers that correlate with successful oral immunotolerance induction through gradual dietary exposure to baked allergens.
38 studies on the registry are indexed under Egg Hypersensitivity; 9 are open to participants now.
This study's enrollment of 148 is above the median of 73 across 27 interventional studies indexed under Egg Hypersensitivity.
Browse Egg Hypersensitivity studies →Fundació Sant Joan de Déu is the lead sponsor of 70 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Baked Group 1: consume a daily fixed low dose of baked milk (0.0375g of milk protein) or baked egg (0.11 g of egg protein).
Dietary Supplement: Dietary intervention using cookies containing milk or egg low dose.
Control Group 1: strict avoidance diet, excluding all milk or egg (as appropriate) and any foods containing them.
Baked Group 2: continue a daily high dose of baked milk (0.55 g of milk protein) or baked egg (1.1 g of egg protein).
Dietary Supplement: Dietary intervention with cow's milk or egg baked cookies high dose
Avoidance
Baked Group 1: consumed a daily fixed low dose of baked milk or egg (0.0375 g of milk protein or 0.11 g of egg protein) for 6 months, followed by an additional increase at that time (0.075 g or 0.22 g).
Baked Group 2: continued a daily high dose of baked milk (0.55 g of milk protein or 1.1g egg protein) for 6 months. An increase dose is given at that time (1.1g cow's milk or 2g egg protein).
1. To evaluate proportion of children who develop tolerance to raw milk or cooked/raw egg at 12 months.
Proportion of participants who achieve clinical tolerance to raw cow's milk or cooked/raw egg following 12 months of intervention. All participants underwent a controlled oral food challenge (OFC) in day's hospital. The intervention will be evaluated positively if the participant become tolerant. An increase in the reaction threshold dose relative to the initial OFC will also be considered favorable. If symptoms appear immediately, the patient will be considered allergic.
Time frame: 12 months from enrollment
Change in immunologic markers (IgE, IgG4, Tregs, BAT).
Longitudinal changes in immunological biomarkers (specific IgE, IgG4, Tregs, and BAT) over the 12-month study period. The measurements of the biomarkers obtained initially (T0) and after the intervention (T1) were compared, observing a reduction in specific IgE and an increase in IgG4 in the tolerant patients. The BAT has also shown changes in the intervention but the statistical significance must be individualized by food. T-cell cytokine profiling in patients with cow's milk allergy showed no significant changes. Analysis for the egg allergy group is pending.
Time frame: 12 months intervention
Rate of reactions during oral food challenges.
Number and severity of reactions recorded during oral food challenge procedures were obtained T0 and T1. The severity of reactions were classified according to the EACCI position paper 2007.
Time frame: 12 months intervention
Changes in threshold dose triggering reactions.
Variation in the minimum eliciting dose (MED) triggering allergic symptoms in the OFC at T1 was evaluated. An increase in the tolerated allergen dose without a clinical reaction indicates a higher reaction threshold-dose, and this was assessed as favorable after the intervention. This condition would allow the participant to follow a less restrictive diet and, consequently, less concern about food safety.
Time frame: 12 months intervention
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — The following individual participant data will be shared: demographic data (age, sex), clinical outcomes (primary and secondary endpoints), laboratory results, and adverse events. Data will be available beginning 6 months after publication and will remain accessible for 5 years. Data will be shared with qualified researchers affiliated with academic or healthcare institutions, for purposes of academic research or meta-analysis, and can be used for further analysis of the intervention's efficacy, safety profiling, or inclusion in systematic reviews. Study protocol, statistical analysis plan, and informed consent forms (in anonymized format) will also be made available. Requests should be submitted to the corresponding author by email. A data access agreement must be signed, and the research proposal will be reviewed by the study steering committee before approval is granted.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data will be available beginning 6 months after publication
Access criteria: Researchers affiliated with academic or healthcare institutions
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Fundació Sant Joan de Déu